Similar articles for PMID: 12040460

Year	Number of Results
1974	1
1975	1
1979	1
1981	1
1982	1
1986	1
1989	2
1990	1
1991	1
1992	1
1993	3
1994	6
1995	4
1996	3
1997	3
1998	11
1999	10
2000	17
2001	12
2002	17
2003	17
2004	22
2005	14
2006	15
2007	12
2008	7
2009	7
2010	7
2011	9
2012	14
2013	6
2014	4
2015	11
2016	6
2017	7
2018	12
2019	9
2020	6
2021	8
2022	7
2023	2
2024	0

1

T cell activation with systemic agonistic antibody versus local 4-1BB ligand gene delivery combined with interleukin-12 eradicate liver metastases of breast cancer.

Martinet O, Divino CM, Zang Y, Gan Y, Mandeli J, Thung S, Pan PY, Chen SH. Martinet O, et al. Gene Ther. 2002 Jun;9(12):786-92. doi: 10.1038/sj.gt.3301687. Gene Ther. 2002. PMID: 12040460

2

The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.

Xu DP, Sauter BV, Huang TG, Meseck M, Woo SL, Chen SH. Xu DP, et al. Gene Ther. 2005 Oct;12(20):1526-33. doi: 10.1038/sj.gt.3302556. Gene Ther. 2005. PMID: 15973445

3

Rejection of disseminated metastases of colon carcinoma by synergism of IL-12 gene therapy and 4-1BB costimulation.

Chen SH, Pham-Nguyen KB, Martinet O, Huang Y, Yang W, Thung SN, Chen L, Mittler R, Woo SL. Chen SH, et al. Mol Ther. 2000 Jul;2(1):39-46. doi: 10.1006/mthe.2000.0086. Mol Ther. 2000. PMID: 10899826 Free article.

4

Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.

Kim JA, Averbook BJ, Chambers K, Rothchild K, Kjaergaard J, Papay R, Shu S. Kim JA, et al. Cancer Res. 2001 Mar 1;61(5):2031-7. Cancer Res. 2001. PMID: 11280763

5

NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.

Xu D, Gu P, Pan PY, Li Q, Sato AI, Chen SH. Xu D, et al. Int J Cancer. 2004 Apr 20;109(4):499-506. doi: 10.1002/ijc.11696. Int J Cancer. 2004. PMID: 14991570 Free article.

6

Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.

May KF Jr, Chen L, Zheng P, Liu Y. May KF Jr, et al. Cancer Res. 2002 Jun 15;62(12):3459-65. Cancer Res. 2002. PMID: 12067989

7

4-1BB promotes long-term survival in skin allografts treated with anti-CD45RB and anti-CD40L monoclonal antibodies.

Lee J, Lee EN, Kim EY, Lee HJ, Park HJ, Sun CL, Lee SK, Joh JW, Lee KW, Kwon GY, Kim SJ. Lee J, et al. Transplant Proc. 2005 Jan-Feb;37(1):123-5. doi: 10.1016/j.transproceed.2005.01.016. Transplant Proc. 2005. PMID: 15808569

8

A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity.

Yoshida H, Katayose Y, Unno M, Suzuki M, Kodama H, Takemura S, Asano R, Hayashi H, Yamamoto K, Matsuno S, Kudo T. Yoshida H, et al. Cancer Immunol Immunother. 2003 Feb;52(2):97-106. doi: 10.1007/s00262-002-0334-y. Epub 2003 Jan 18. Cancer Immunol Immunother. 2003. PMID: 12594573 Free PMC article.

9

Administration of agonistic anti-4-1BB monoclonal antibody leads to the amelioration of inflammatory bowel disease.

Lee J, Lee EN, Kim EY, Park HJ, Chang CY, Jung DY, Choi SY, Lee SK, Lee KW, Kwon GY, Joh JW, Kim SJ. Lee J, et al. Immunol Lett. 2005 Nov 15;101(2):210-6. doi: 10.1016/j.imlet.2005.06.001. Immunol Lett. 2005. PMID: 16026855

10

NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1BB monoclonal antibodies.

Melero I, Johnston JV, Shufford WW, Mittler RS, Chen L. Melero I, et al. Cell Immunol. 1998 Dec 15;190(2):167-72. doi: 10.1006/cimm.1998.1396. Cell Immunol. 1998. PMID: 9878117

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

284 results

Results by year